| |
COVID Congress: Baseline Characteristics Associated With Clinical Improvement and Mortality in Hospitalized Patients With Severe COVID-19 Treated With Remdesivir
|
| |
| |
Virtual COVID-19 Conference, July 10‒11, 2020
Reported by Jules Levin
Kristen Marks1, Leila Hojat2, Gregory Huhn3, Kathleen Degnan4, ArunaSubramanian5, Mi Young Ahn6, Massimo Galli7, Raffaele Bruno8, Jose Muñoz9, Robert R. Hyland10, XuelianWei10, Christiana Blair10, HuyenCao10, Devi SenGupta10, Anu O. Osinusi10, Diana M. Brainard10, Onyema Ogbuagu11, Philip Robinson12
1Weill Cornell Medicine, New York, NY, USA; 2University Hospitals Cleveland Medical Center, Cleveland, OH, USA; 3Ruth M. Rothstein CORE Center, Chicago, IL, USA; 4Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 5Stanford University, Stanford, CA, USA; 6Seoul Medical Center, Seoul, Korea; 7Università degliStudidi Milano, Milano, Italy; 8University of Pavia, Pavia, Italy; 9Hospital Clinic de Barcelona, Barcelona, Spain; 10Gilead Sciences, Inc., Foster City, CA, USA; 11Yale University, New Haven, CT, USA; 12Hoag Hospital, Newport Beach, CA, USA
|
|
| |
| |
|
|
|
